Renal failure requiring hemodialysis in two patients with metastatic breast cancer treated with everolimus. (May 2015)

• Record Type: Journal Article
• Authors: Kuo, James C; Gorddard, Nicole; Stuart-Harris, Robin
• Is Part Of: Breast cancer management. Volume 4:Number 3(2015)
• Page Start: 129
• Page End: 134
• Publication Date: 2015-05
• Subjects: acute renal failure -- adverse drug events -- everolimus -- hemodialysis -- metastatic breast cancer -- mTOR inhibitors; Breast -- Cancer -- Periodicals; Breast -- Cancer -- Treatment -- Periodicals; 616.9944905
• DOI: 10.2217/bmt.15.6
• Languages: English
• ISSNs: 1758-1923

Abstract

SUMMARY : Everolimus, an mTOR inhibitor, has been shown to improve progression-free survival in patients with hormone receptor-positive metastatic breast cancer receiving exemestane, an aromatase inhibitor. Everolimus has also been found to be an effective treatment for a number of other malignancies. Renal failure in cancer patients receiving everolimus is rare. We report two cases of renal failure requiring hemodialysis in patients with hormone receptor-positive metastatic breast cancer who were receiving everolimus and exemestane.